Skip to main content
Clinical Trials/KCT0005145
KCT0005145
Recruiting
未知

Development of Biomarkers for Diabetic Nephropathy based on Exosome Multi-Omics Study

Korea University Ansan Hospital0 sites260 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Korea University Ansan Hospital
Enrollment
260
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • ? inclusion criteria (Type 2 diabetes)
  • Type 2 diabetes patients aged 40\-80
  • Patients who have been followed for more than 2 years
  • Patients whose albumin\-creatinine ratio and estimated glomerular filtration rate were measured two or more times before consent to study participation.
  • estimated glomerular filtration rate \=30 ml/min/1\.73m2
  • ? Inclusion criteria (healthy adult)
  • 40\-80 years healthy adult without hypertension, diabetes and chronic kidney disease
  • Subjects who have been followed for more than 2 years at the Korea University Ansan Hospital Genome Cohort (The Korean Genome and Epidemiology Study, KoGES)
  • estimated glomerular filtration rate \=60 ml/min/1\.73m2

Exclusion Criteria

  • Patients with type 1 diabetes or a history of diabetic ketoacidosis or end stage renal diseas
  • Patients diagnosed with chronic kidney disease not related to diabetes
  • Patients with uncontrolled blood pressure (systolic blood pressure \> 180 mmHg even after taking antihypertensive drugs) or patients taking 4 or more antihypertensive drugs
  • kidney transplant, single kidney, or genetic kidney disease
  • History of dialysis or acute kidney damage
  • Other severe systemic diseases or body mass index \<18\.5 kg / m2
  • History of malignancy within the last 5 years
  • Long\-term use of nephrotoxic drugs (eg, non\-steroidal anti\-inflammatory drugs, lithium) (over 3 months)
  • Use of steroids (over 3 weeks) or systemic immunosuppressants
  • Subjects deemed inappropriate for clinical studies (pregnant women, severe systemic diseases, psychiatric patients, etc.)

Outcomes

Primary Outcomes

Not specified

Similar Trials